Guitarist Jack Simmons unpacks his wild ESP refinish, why pinch harmonic riffs are the best riffs, and how he grabbed Ronnie ...

The ASX has inched up on Monday as Trump cooled his tariff tantrum. Coal stocks took a hit from a Hunter Valley court ruling.

Viking Therapeutics ( ($VKTX) ) has risen by 7.76%. Read on to learn why. Viking Therapeutics has seen a notable 7.76% ...

Viking Therapeutics reported a solid financial standing with $808 million in cash, cash equivalents, and short-term investments. This strong cash position provides a substantial financial runway to ...

That being said, we’re here with a list of the 10 most profitable new stocks to buy now. We sifted through the Finviz stock screener to compile a list of the top companies that went public in the last ...

Viking Therapeutics has strong R&D, dual-track obesity drugs, and solid cash runway. Click here to read an analysis of VKTX ...

CEO Emma Walmsley’s 40-bln-pound 2031 sales target looks fanciful after another disappointing drug trial. A healthy balance ...

We came across a bullish thesis on Viking Therapeutics, Inc. on r/wallstreetbets subreddit by Dritzz-9966. In this article, ...

Brian Lian, President and CEO, reported that "the Viking team continued to focus on execution of our core clinical strategy," emphasizing advancement of both oral and subcutaneous VK2735 programs. "We ...

Loss per share was $(0.58), falling short of analyst expectations by $(0.13), or 29.1% (GAAP, Q2 2025). - Research and development expenses rose to $60.2 million in Q2 2025, up from $23.8 million in ...

Viking Therapeutics shares fall in Wednesday's after-hours session after the company reported financial results for the ...

Investing.com -- Viking Therapeutics, Inc. (NASDAQ: VKTX) reported a wider-than-expected second quarter loss on Wednesday, sending shares down 4.2% as investors reacted to the earnings miss despite ...